HK inno.NHK이노엔
195940 · KOSDAQ · ₩195940 · HK이노엔
Analyst target price
Average target
₩61,500
Upside
+79.6%
Range ₩55,000 – ₩68,000 · 2 brokers (latest target within 6 months)
Buy 1
Consensus target vs price, 2 years
Earnings estimates
Brokers' earnings estimates and how they've been revised, with Pro.
Unlock with ProBroker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 28 | Mirae Asset Securities | HK inno.N (195940/Buy) Obscured Growth to Become Visible from 2027 | Buy | — | — | −1.3% | Read ↗ | |
| Oct 13 | Yuanta Securities Korea | Just a few months left until '27 | Buy | ₩68,000 | New | +98.5% | −8.8% | Read ↗ |
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
Reported in the news
| Date | Broker | Target | Change | Rating | Source |
|---|---|---|---|---|---|
| Oct 16 | — | ₩59,000 | Cut | — | Reported by Seoul Economic Daily |
| Oct 16 | — | — | Cut | — | Reported by Etoday |
| Oct 12 | — | ₩67,000 | — | Reported by The Financial News | |
| Oct 12 | NH Investment & Securities | ₩55,000 | Maintained | — | Reported by Edaily |
Target prices and ratings as news headlines report them, for every broker, including the ones whose reports we don't collect. Only what the headline says; open the article for the rest. Not financial advice.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
HK inno.N's share price has fallen sharply over the past year, while its reported profits have grown and Q3 operating profit was roughly flat.
HK inno.N is a Korean drugmaker whose prescription drugs make up about 93% of sales. Trailing results to H1 2026 show revenue of ₩1.08T and operating income of ₩129B, and the shares trade at about ₩34,700, near the lower half of their 52-week range. Preliminary Q3 2026 results were filed on 28 October 2026, showing operating profit of about ₩26B, up 0.6% year on year.
What stands out
- Trailing operating margin is about 12% and net margin about 8%, both higher than the 2025 full-year levels of 10.4% and about 7%.
- Revenue grew 18.5% in 2025, but Q3 2026 revenue was reported as slightly down, according to news coverage.
- Share price is down 32.4% over one year and 11.6% over one month, against a 52-week range of ₩32,600 to ₩58,600.
- Its trailing P/E is about 11.5 and P/B about 0.7, below most listed peers in the data, though the data gives no reason for this gap.
- Exports of Caverjet rose 113% in Q3, per one news headline, while news reports cite a keycap inventory adjustment and weak China royalties as drags on earnings.
- Borrowings of ₩431B exceed cash of ₩68B, and the data lists a liabilities-to-equity ratio of 49.7%.
What to watch
- Full Q3 2026 quarterly report and whether the preliminary figures are confirmed.
- Whether the keycap inventory adjustment and China royalty weakness continue into coming quarters.
- Trend in foreign ownership, which fell from 13.7% to 11.4% over the past 60 days.
Data as of Oct 28, 2026 · written 2d ago
This is not financial advice.
Also known as: HK inno.N / HK이노엔 / 195940 / KRX:195940
Source: KRX statistical information